GSK 1292263
- Catalog NO.:A25170
- CAS No. : 1032823-75-8
- Molecular Formula:C23H28N4O4S
- Molecular Weight: 456.56
Note*
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Bulk Inquiry
1. Please click the to confirm the discount and stock quantity.
2. Click“Bulk Inquiry”to ask for quotations of other quantity.
3. The price does not include shipping and bank charges.
Quality Control&SDS
SDS
Product Details
CAS Number | 1032823-75-8 | Appearance | Crystalline solid |
Catalog Number | A25170 | MDL Number | MFCD18385004 |
Molecular Formula | C23H28N4O4S | Molecular Weight | 456.56 |
Boiling Point | Melting Point | ||
Flash Point | Density | ||
Synonyms | 5-((1-(3-isopropyl-1,2,4-oxadiazol-5-yl)piperidin-4-yl)methoxy)-2-(4-(methylsulfonyl)phenyl)pyridine | ||
Storage Condition | Store in a tightly closed container,in a cool and dry place |
Safety
GHS Pictogram | |||
Signal Word | Warning | UN Number | |
Hazard Statements | H302-H315-H320-H335 | Class | |
Precautionary Statements | P261-P280-P301+P312-P302+P352-P305+P351+P338 | Packing Group |
Description
GSK-1292263 is a novel GPR119 agonist that is currently under development for the treatment of type 2 diabetes. GSK1292263 improves glucose regulation in animal models of diabetes, but has no effect on plasma glucose in type 2 diabetics. Unexpectedly, GSK1292263 lowered fasting LDLc and triglycerides (TG), while increasing HDLc in the diabetic subjects. GSK1292263 has significant effects on plasma lipids and lipoprotein particles in dyslipidemic patients when dosed alone and with atorvastatin. |